Zynerba Pharmaceuticals, Inc.
DelistedCIK 1621443fmd_06V8KGMN6M5Z72N8ZQVDEMD12QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2023, 39 periods
Latest annual · FY2018
Millions- Total revenues
- 0
- Operating income
- (35)
- Net income
- (35)
- Free cash flow
- (23)
Latest quarter · Q2 FY2023
Millions- Operating income
- (11)
- Net income
- (11)
- Free cash flow
- (8)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
Zynerba Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$35.3 million | -$36.8 million | 10-K 2023-03-28 · proof | |
| Net income | -$35 million | -$37.3 million | 10-K 2023-03-28 · proof | |
| Cash from operating activities | -$23 million | -$33.5 million | 10-K 2023-03-28 · proof | |
| Free cash flow | -$23.2 million | -$33.5 million | 10-K 2023-03-28 · proof | |
| Total assets | $55.5 million | $81.2 million | -31.6% | 10-K 2023-03-28 · proof |
| Total liabilities | $9.3 million | $10.3 million | -9.4% | 10-K 2023-03-28 · proof |
| Cash and cash equivalents | $50.6 million | $67.8 million | -25.3% | 10-K 2023-03-28 · proof |
- What was Zynerba Pharmaceuticals, Inc.'s operating income in fiscal 2022?
- Zynerba Pharmaceuticals, Inc. reported operating income of -$35.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$36.8 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
- What was Zynerba Pharmaceuticals, Inc.'s net income in fiscal 2022?
- Zynerba Pharmaceuticals, Inc. reported net income of -$35 million for fiscal 2022 (the year ended Dec 31, 2022), against -$37.3 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
- What was Zynerba Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2022?
- Zynerba Pharmaceuticals, Inc. reported cash from operating activities of -$23 million for fiscal 2022 (the year ended Dec 31, 2022), against -$33.5 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
- What was Zynerba Pharmaceuticals, Inc.'s free cash flow in fiscal 2022?
- Zynerba Pharmaceuticals, Inc. reported free cash flow of -$23.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$33.5 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
- What are Zynerba Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2022, Zynerba Pharmaceuticals, Inc. reported total assets of $55.5 million, against $81.2 million a year earlier (-31.6%). Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
- What are Zynerba Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2022, Zynerba Pharmaceuticals, Inc. reported total liabilities of $9.3 million, against $10.3 million a year earlier (-9.4%). Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
- What are Zynerba Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Zynerba Pharmaceuticals, Inc. reported cash and cash equivalents of $50.6 million, against $67.8 million a year earlier (-25.3%). Source: the 10-K filed with the SEC on Mar 28, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1621443&period_type=annual&limit=5"Information only, not investment advice.